Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $1.6 million.

  • Enanta Pharmaceuticals' Change in Receivables rose 5027.99% to $1.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $775000.0, marking a year-over-year increase of 27032.97%. This contributed to the annual value of $236000.0 for FY2025, which is 11199.19% up from last year.
  • Enanta Pharmaceuticals' Change in Receivables amounted to $1.6 million in Q4 2025, which was up 5027.99% from -$1.5 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' Change in Receivables' 5-year high stood at $4.1 million during Q4 2021, with a 5-year trough of -$11.6 million in Q1 2021.
  • Over the past 5 years, Enanta Pharmaceuticals' median Change in Receivables value was $591500.0 (recorded in 2022), while the average stood at -$1.2 million.
  • In the last 5 years, Enanta Pharmaceuticals' Change in Receivables tumbled by 132502.98% in 2023 and then soared by 34308.39% in 2024.
  • Over the past 5 years, Enanta Pharmaceuticals' Change in Receivables (Quarter) stood at $4.1 million in 2021, then plummeted by 44.33% to $2.3 million in 2022, then tumbled by 119.45% to -$441000.0 in 2023, then soared by 343.08% to $1.1 million in 2024, then skyrocketed by 50.28% to $1.6 million in 2025.
  • Its Change in Receivables stands at $1.6 million for Q4 2025, versus -$1.5 million for Q3 2025 and $1.5 million for Q2 2025.